Bayer and Thermo Fisher collaborate to increase patient access to precision cancer medicines
Singapore, March 20 -- Bayer AG and Thermo Fisher Scientific have announced to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) together. These will help identify patients who may benefit from Bayer's growing portfolio of precision cancer therapies by offering decentralised genomic testing and rapid turnaround time.
The CDx will be developed using Thermo Fisher's Oncomine Dx Express Test on the Ion Torrent Genexus Dx System, a fully integrated next-generation sequencing (NGS) platform that can deliver results on a patient's tumour or liquid biopsy sample in as little as 24 hours.
According to Christine Roth, Member of the Executive Committee of Bayer's Pharmaceuticals Division and Head of the Oncology Str...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.